Skiplinks

Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Sacubitril/valsartan in heart failure: differing added benefit

2016-06-16 Due to a subgroup effect, there is an indication of a minor added benefit for patients with diabetes, and an indication of a considerable added benefit for patients without diabetes.  read more Link to "Sacubitril/valsartan in heart failure: differing added benefit"

Osimertinib in lung cancer: added benefit not proven

2016-06-15 Due to a lack of studies of direct comparisons the manufacturer subsequently submitted historical comparisons, but the visible effects were not large enough for conclusions on added benefit.  read more Link to "Osimertinib in lung cancer: added benefit not proven"

Cobimetinib in advanced melanoma with BRAF V600 mutation: added benefit now considerable

2016-06-02 Further advantages of the drug in comparison with the comparator therapy resulted from the analyses subsequently submitted by the drug manufacturer in the commenting procedure.  read more Link to "Cobimetinib in advanced melanoma with BRAF V600 mutation: added benefit now considerable"

Ramucirumab in colorectal and lung cancer: partly added benefit, partly lesser benefit

2016-06-01 There were effect modifications in both new therapeutic indications: Depending on sex or age, advantages or disadvantages predominate.  read more Link to "Ramucirumab in colorectal and lung cancer: partly added benefit, partly lesser benefit"

Empagliflozin in type 2 diabetes: added benefit for single agent and fixed combination again not proven

2016-06-01 The dossiers had the same weaknesses as in 2014. Data from the large study EMPA-REG-Outcome additionally submitted were unsuitable for an assessment of the added benefit in Germany.  read more Link to "Empagliflozin in type 2 diabetes: added benefit for single agent and fixed combination again not proven"

loading …

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
S15-01 Newborn screening for tyrosinaemia type 1 using tandem mass spectrometry on the preliminary report 2016-07-14
N16-01 Active knee motion devices for the treatment of anterior cruciate ligament ruptures on the report plan 2016-06-30

Commissions advertised

Commissions advertised

Currently no commissions advertised.


Easily understandable information for patients and the general community

Ramucirumab (Cyramza) for advanced lung cancer

Ramucirumab (trade name: Cyramza) has been approved in Germany since January 2016 for the treatment of advanced lung cancer. The drug is used in combination with docetaxel. It is an option for adult patients with non-small cell lung carcinoma who have already had platinum-based chemotherapy.  read more (Link to "Ramucirumab (Cyramza) for advanced lung cancer" – opens in a new window)

to top

Glossary entries